MARKET OUTLOOK QUESTIONS ANSWERED What are the treatment drivers and goals for [[indication]]? What drug attributes are key influencers, which have limited impact, and which are hidden…
Drug treatment of glaucoma focuses on reducing/controlling intraocular pressure and preserving visual function. Given the availability of multiple drug classes—i.e., prostaglandin analogues, beta…
Antipsychotics are the cornerstone of schizophrenia treatment, with the crowded atypical and typical antipsychotic drug classes resulting in a complex treatment algorithm. Given the genericization…
Introduction: NASH is characterized by a buildup of excess lipid (steatosis) in the liver, resulting in inflammation and eventually liver damage, leading to fibrosis and subsequently cirrhosis and…
MARKET OUTLOOK Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide spectrum of clinical symptoms ranging from…
Ulcerative colitis (UC) patients, particularly those with more mild disease activity, will be prescribed a conventional therapy (e.g., 5-ASAs) as first-line treatment; there are multiple generics…
Painful diabetic neuropathy (PDN) in the United States is defined as having had numbness, loss of feeling, or painful sensations in the feet within the last three months. PDN is managed by multiple…
In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as IL-12/23 inhibitor Stelara (Janssen), have been leading the U.S. psoriasis biologics market. However, the…
The primary goal of ulcerative colitis (UC) treatment is to induce and maintain remission with few to no clinical symptoms remaining. Conventional therapies (e.g., 5-ASAs, corticosteroids) are…
Painful diabetic neuropathy (PDN) in the United States is defined as having had numbness, loss of feeling, or painful sensations in the feet within the last three months. PDN is managed by multiple…
MARKET OUTLOOK Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years. Intensive…
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only other oral targeted therapy, besides Celgene’s PDE-4 inhibitor, Otezla,…
MARKET OUTLOOK Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins, but DRG anticipates that the number of treatment options will grow over the next ten years. Intensive…
Atopic Dermatitis | Emerging Therapies | Eucrisa | US is a three-wave series that tracks the introduction of Pfizer’s Eucrisa for the treatment of AD. The series is based on primary research data…